Respiratory Syncytial Virus (RSV)

Respiratory syncytial virus (RSV) is the second leading cause of infant mortality and a major cause of older adult mortality. At Julius Clinical, we are dedicated to using our full capabilities in support of the testing of novel treatments that can potentially reduce the spread and severity of RSV.

We are an academic CRO that is dedicated to testing novel treatments that might reduce the spread and severity of RSV. We rely on collaborations with world renown scientific leaders, our operational expertise, our proprietary site networks and a partnership with a ReSViNET, which has a proven RSV research track record.

Meet our scientific leader for RSV clinical trials

We collaborate with Prof. dr. Louis Bont, a paediatrician specialized in infectious diseases and immunology at the University Medical Centre (UMC) Utrecht, and Chairman of the ReSViNET foundation. He supervises RSV related studies, such as the RSV GOLD mortality study (funded by the Bill & Melinda Gates Foundation), and is adviser to the World Health Organization (WHO) for RSV vaccine development.

Scientific networks

How we operate

Access to healthcare in sub-Saharan countries remains a challenge, resulting in profound inequities in health in the region. In response to these challenges, Julius Clinical and Julius Global Health (part of the University Medical Center Utrecht) have created Africa Clinical, a network of local clinical investigators and institutes who are committed to improving healthcare and specifically the health of the sub-Saharan population.

Our partnership

Who we work with

We established ReSViNET in 2014, and since 2018, ReSViNET has been a foundation — a financially and otherwise independent regulated entity. Julius Clinical works closely with ReSViNET to provide operational support to RSV clinical trials and observational studies. Our operational team has extensive experience in coordinating these studies, and ReSViNET has access to sites in countries across the globe, providing fast recruitment and high retention rates.

Success stories

Proven track-record

Surveillance study, Global

Ongoing

300 Patients | 2 Countries | 3 Sites

Global surveillance study of Respiratory Syncytial Virus (RSV).

Retrospective evaluation, Global

Completed

100 Patients | 5 Countries | 5 Sites

Retrospective evaluation of respiratory specimens collected from infants for respiratory syncytial virus (RSV) analysis.

Observational study, Global

4250 Patients | 17 Countries | 19 Sites

Monitoring of RSV to determine the molecular heterogenity of RSV in children.

Related webinars

Webinars

Infectious Diseases & Vaccines, RSV

Webinar: “RSV and Asthma”

On September 6, our partner ReSViNET presented the webinar: “RSV and Asthma” Prof Tina Hartert, MD, MPH shared her insights on RSV in relationship to asthma. Her study of almost two thousand children has identified that delay in early life ...

More webinars

Respiratory Syncytial Virus